Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompLEEment-1: ribociclib plus letrozole in HR-positive, HER2-negative advanced breast cancer
MOH_2017-03-14_000238Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ribociclib and letrozole in breast cancer, sponsored by Novartis. Started Mar 2017; status: completed.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-03-14_000238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000238.